A Phase IIa, Placebo Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO-11006 Inhalation Solution in Patients With Acute Respiratory Distress Syndrome
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2018
At a glance
- Drugs BIO-11006 (Primary)
- Indications Respiratory distress syndrome
- Focus Adverse reactions; Proof of concept
- Sponsors BioMarck Pharmaceuticals
- 13 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 13 Feb 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Aug 2018.
- 02 Oct 2017 Status changed from not yet recruiting to recruiting.